




Fact Sheet

2010 Q1 Update

Corporate Profile:

Since its founding in 2000, ev3 has been dedicated to developing innovative, breakthrough and clinically proven technologies and solutions for the treatment of peripheral vascular and neurovascular diseases. ev3's products are used by endovascular specialists to treat a wide range of peripheral vascular and neurovascular diseases and disorders. The company offers a comprehensive portfolio of treatment options, including the primary interventional technologies used today – peripheral angioplasty balloons, stents, plaque excision systems, embolic protection devices, liquid embolics, embolization coils, flow diversion, thrombectomy catheters and occlusion balloons. More information about the company and its products can be found at www.ev3.net.



Analyst Coverage[†]:

Exchange: NASDAQ
Ticker: EVVV

CHARLEY JONES
Barrington Research
cjones@brai.com

JOANNE WUENSCH
BMO Capital Markets
joanne.wuensch@bmo.com

JASON MILLS
Canaccord Adams
jason.mills@canaccordadams.com

CHARLES HAFF
Dougherty Markets
chaff@doughertymarkets.com

MICHAEL WEINSTEIN
JPMorgan
mike.weinstein@jpmorgan.com

JOSH JENNINGS
Jefferies & Company, Inc.
joshjennings@jefferies.com

DAVID LEWIS
Morgan Stanley
david.r.lewis@morganstanley.com

JOSHUA ZABLE
Natixis Bleichroeder, Inc.
joshua.zable@blr.natixis.com

THOMAS GUNDERSON
Piper Jaffray
thomas.j.gunderson@pjc.com

LARRY NEIBOR
R.W. Baird
lneibor@rwbaird.com

TOM KOUCHOUKOS
Stifel Nicolaus & Company
kouchoukost@stifel.com

BETH SENKO
Williams Capital Group
senko@willcap.com

Investor Contact:

JULIE TRACY
Sr. Vice President
Chief Communications Officer
OFFICE 949-680-1375
MOBILE 209-613-6945
jtracy@ev3.net

ev3 Inc.
Corporate World Headquarters
3033 Campus Drive
Plymouth, MN 55441

[†] ev3 is followed by the analysts listed. Please note that any opinions, estimates or forecasts regarding ev3's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of ev3 or its management. ev3 does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.

Recent Developments:

April 29, 2010

ev3 Inc. Reports 2010 First Quarter Financial Results and Increases Full-Year 2010 Revenue and Earnings Guidance

First Quarter Financial Results: ev3's net sales were \$123.9 million in the first quarter 2010 versus \$100.4 million in the comparable quarter of 2009. First quarter net sales increased 23% versus the first quarter 2009 and 21% on a constant currency basis. ev3's net income for the first quarter of 2010 increased to \$9.9 million, or \$0.09 per diluted share. ev3's non-GAAP adjusted net income was \$22.3 million, or \$0.20 per diluted share, in the first quarter of 2010, compared to adjusted net income of \$7.1 million, or \$0.07 per diluted share, in the first quarter 2009.

Outlook: ev3 has increased its full-year guidance and now expects fiscal year 2010 net sales to be in the range of \$520 to \$530 million compared to \$449.1 million of net sales in 2009. ev3 expects non-GAAP adjusted earnings per share to be in the range of \$0.87 to \$0.92 per diluted share based on approximately 115.4 million shares outstanding. ev3's adjusted net earnings per share guidance excludes estimated amortization expense of \$26.0 million, non-cash stock-based compensation of \$15.5 million, and charges relating to the estimated change in fair value of the future contingent consideration associated with the Chestnut acquisition of \$17.2 million.

The company expects second quarter of 2010 net sales to be in the range of \$129 to \$133 million over the second quarter of 2009. ev3 expects non-GAAP adjusted earnings per share to be in the range of \$0.18 to \$0.21 per diluted share based on approximately 115.1 million shares outstanding. ev3's non-GAAP adjusted earnings per share for the second quarter of 2010 exclude estimated amortization expense of \$6.5 million, non-cash stock-based compensation of a \$3.9 million and charges relating to the estimated change in fair value of the future contingent consideration associated with the Chestnut acquisition of \$8.1 million.

To access the archived webcast and reconciliations of the non-GAAP financial measures used above to the most comparable U.S. GAAP measures, go to <http://ir.ev3.net>.

April 26, 2010

ev3 Inc. Announces Completion of Patient Enrollment in DURABILITY II Study

Study to Evaluate Patency and Fracture Resistance of the EverFlex Self-Expanding Stent System for the Treatment of Peripheral Arterial Disease

ev3 Inc. (Nasdaq:EVVV) announced the completion of patient enrollment in the DURABILITY II trial, a prospective, multi-center, single-arm study evaluating the EverFlex(R) Self-Expanding Stent System for the treatment of superficial femoral artery (SFA) and proximal popliteal lesions. The DURABILITY II study will support a planned Premarket Approval (PMA) filing with the U.S. Food and Drug Administration to obtain approval of the EverFlex Self-Expanding Stent System for use in the SFA.

The DURABILITY II study enrolled a total of 287 patients at 44 centers in the U.S. and Europe and was the first to employ the Performance Goal developed by the VIVA Physicians, Inc. (VPI) to facilitate more rapid and rigorous evaluation of devices for vascular intervention. The VPI Performance Goal allows evaluation of primary patency of the EverFlex stent at 12 months post-intervention as compared to historical averages for balloon angioplasty. The DURABILITY II study is also the first to evaluate a 200 mm length stent for use in treating peripheral arterial disease (PAD) in the legs.

"With the high incidence of peripheral artery disease that occurs each year in the U.S., ev3 is committed to developing breakthrough therapies to treat this devastating disease," stated Robert Palmisano, ev3's President and Chief Executive Officer. "We believe our EverFlex Self-Expanding Stent System will provide excellent and lasting clinical results as well as improved quality of life for individuals who suffer from PAD."

April 8, 2010

ev3 Inc. Announces Supply Agreement With MEDRAD, Inc. in Preparation for DEFINITIVE AR Pilot Trial

Groundbreaking Study Will Evaluate the Combination of Hawk Plaque Excision and the Cotavance Drug-Eluting Angioplasty Balloon for the Treatment of Lower Extremity Peripheral Arterial Disease

ev3 Inc. (Nasdaq:EVVV) announced the initiation of a supply agreement with MEDRAD Interventional(TM)/Possis(R). Under terms of the agreement, MEDRAD will make available their Cotavance(TM) peripheral drug-eluting balloon angioplasty catheter with Paccocath(R) technology for study in combination with ev3's SilverHawk(R) and TurboHawk(TM) Plaque Excision Systems for use in the DEFINITIVE AR European pilot study for treating lower extremity peripheral arterial disease (PAD).

The DEFINITIVE AR (Anti-Restenosis) study is a prospective, multicenter, randomized pilot study evaluating the use of either the TurboHawk or SilverHawk Plaque Excision System followed by treatment with the Cotavance drug-eluting balloon catheter versus the Cotavance balloon catheter alone in patients with peripheral arterial disease. The pilot study will be led by Professor Thomas Zeller, MD, of Herz-Zentrum Bad Krozingen in Bad Krozingen, Germany and Professor Gunnar Tepe, MD, of Klinikum Rosenheim in Rosenheim, Germany.

The pilot study will evaluate up to 125 patients in Europe and is anticipated to begin in the second half of 2010. It is anticipated a global multicenter pivotal trial will follow the completion of the pilot study.

"We are pleased to announce this collaboration with MEDRAD and our plans for the DEFINITIVE AR pilot study," stated Robert Palmisano, ev3's president and chief executive officer. "Despite recent advances, restenosis remains a significant issue when treating peripheral arterial disease, especially in patients with complex disease such as diabetes and severely calcified lesions. We believe that the Hawk Plaque Excision Systems' unique ability to remove the plaque layer - thereby achieving an optimal vessel lumen - in combination with the Cotavance drug-eluting balloon catheter will provide valuable data for the clinical community in treating peripheral arterial disease."

NEUROVASCULAR | PERIPHERAL VASCULAR

Access · Balloons · Carotid · Embolic Coils · Embolic Protection · Liquid Embolics · Plaque Excision · Procedural Support · Retrieval Devices · Stents

ev3 Corporate

World Headquarters
Peripheral Vascular
3033 Campus Drive
Plymouth, MN 55441
USA
PH +1 763 398 7000
FX +1 763 398 7001
Cust Srvc +1 800 716 6700

ev3 Neurovascular

9775 Toledo Way
Irvine, CA 92618
USA
PH +1 949 837 3700
FX +1 949 837 2044

ev3 Europe

International Headquarters
106-108 rue La Boétie
75008 Paris
France
PH +33 156 88 59 10
FX +33 156 88 59 11

www.ev3.net

